Advanced Neuromodulation Systems
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application for the company's totally implanted pulse generator (IPG) spinal cord stimulation for relief of chronic pain of the trunk will be submitted to FDA later this month, ANS announces April 4. Separately, the company will continue to appeal the agency's Feb. 23 denial of its petition to downclassify the SCS IPG from Class III to Class II (1"The Gray Sheet" March 5, 2001, p. 10)
You may also be interested in...
CDRH Shocks ANS, Denies Downclassification of Spinal Cord Stimulator
FDA inspections of design controls under the Quality Systems Regulation do not provide enough assurance against device failure to allow the downclassification of the Class III totally implanted spinal cord stimulator (SCS) for pain relief, the agency maintains in a Feb. 23 letter to Advanced Neuromodulation Systems.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.